GSA Capital Partners LLP Has $1.09 Million Stock Position in Theravance Biopharma, Inc. $TBPH

GSA Capital Partners LLP trimmed its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 36.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,379 shares of the biopharmaceutical company’s stock after selling 33,802 shares during the quarter. GSA Capital Partners LLP’s holdings in Theravance Biopharma were worth $1,092,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after buying an additional 54,152 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Theravance Biopharma by 6.2% in the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock worth $11,193,000 after buying an additional 44,634 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma during the 3rd quarter valued at $10,611,000. UBS Group AG raised its stake in Theravance Biopharma by 10.9% during the 4th quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock valued at $10,673,000 after purchasing an additional 56,255 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Theravance Biopharma by 16.5% during the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock valued at $5,952,000 after purchasing an additional 76,417 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TBPH shares. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. HC Wainwright upped their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. BTIG Research reiterated a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. Finally, Weiss Ratings cut shares of Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.83.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $16.34 on Friday. Theravance Biopharma, Inc. has a 52-week low of $9.10 and a 52-week high of $21.03. The stock has a market cap of $842.33 million, a price-to-earnings ratio of 7.43 and a beta of 0.19. The firm has a fifty day moving average of $15.94 and a 200-day moving average of $17.53.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, sell-side analysts predict that Theravance Biopharma, Inc. will post 0.95 earnings per share for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.65% of the stock is currently owned by corporate insiders.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.